Ocumetics Technology Corp (TSE:OTC)
:OTC
Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.55
C$0.02(6.45%)
At close: 4:00 PM EST
C$0.55
C$0.02(6.45%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.99
Previous CloseN/A
Volume36.17K
Average Volume (3M)77.99K
Market Cap
C$28.31M
Enterprise ValueC$33.14M
Total Cash (Recent Filing)C$464.04K
Total Debt (Recent Filing)C$5.30M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding53,414,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Product FocusA focused product strategy centered on an accommodating IOL concentrates R&D resources and expertise on a single clinically defined solution. If regulatory approval and clinical adoption are achieved, this specialization supports durable commercialization pathways and repeatable procedures tied to cataract treatment.
Regulatory/Commercialization PathwayActive progression toward regulatory approval is a structural value driver for medtech firms: achieving approvals converts R&D into addressable commercial sales, reduces technical risk, and creates a defensible pathway to recurring procedure-based revenue and long-term market presence.
Improving Cash Flow TrendAlthough cash flow remains negative, improvement in free cash flow growth versus prior periods signals operational discipline or cost control gains. Sustained improvement would lengthen runway, reduce near-term financing pressure, and increase the odds of bridging to commercialization.
Bears Say
No Revenue / Unproven CommercializationAbsence of revenue and recurring negative gross profit indicate the company has not commercialized its technology. This is a fundamental risk: long-term viability depends on successful regulatory, clinical and commercial execution to convert R&D into sustainable sales, which is unproven.
Persistent Cash BurnMaterial negative operating and free cash flow demonstrate ongoing cash burn that must be financed externally. Over time, persistent cash deficits increase dilution or debt needs, raising execution risk and potentially constraining investment in trials, regulatory work, or commercialization.
Weakened Balance Sheet And Rising DebtNegative equity and materially increased debt weaken financial flexibility and raise refinancing risk. A stretched balance sheet limits the company's ability to fund development or absorb setbacks, potentially forcing dilutive financing or higher-cost capital that impairs long-term stability.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$28.31M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 53,414,104 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is headquartered in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―